art.22730

CHILDHOOD SYMPTOMS ASSOCIATED WITH CHRONIC WIDESPREAD PAIN IN ADULTHOOD
an epidemiological view. Best Pract Res Clin Rheumatol 1999;13:
403–14.
32. Jones GT, Silman AJ, Macfarlane GJ. Parental pain is not
associated with pain in the child: a population based study. Ann
Rheum Dis 2004;63:1152–4.
33. Macfarlane GJ, Croft PR, Schollum J, Silman AJ. Widespread pain:
is an improved classification possible? J Rheumatol 1996;23:1628–32.
34. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ. The
association between chronic widespread pain and mental disorder:
a population-based study. Arthritis Rheum 2000;43:561–7.
35. Wigers SH. Fibromyalgia outcome: the predictive value of symptom duration, physical activity, disability pension, and critical life
events;—a 4.5 year prospective study. J Psychosom Res 1996;41:
235–43.
Errata
DOI 10.1002/art.22729
In the article by York et al published in the March 2007 issue of Arthritis & Rheumatism (pp. 1010–1020), the panels of
Figure 1 are referred to incorrectly in the legend, because the figure was published in the wrong orientation. The corrected
legend (panels corresponding to the way the figure was actually published) is as follows: “Cluster of interferon
(IFN)–regulated genes expressed by peripheral blood mononuclear cells in a subset of patients with systemic sclerosis
(SSc) and healthy control subjects. Genes were clustered by unsupervised, hierarchic clustering after selection of genes
that were expressed a mean 1.5-fold higher in SSc patients compared with healthy subjects and after filtering out genes
with a mean expression value ⱕ50. The top right panel shows a section of the hierarchic clustering (mostly duplicated in
the top left panel), and the bottom panels show expanded IFN-regulated gene clusters (expanded areas boxed in yellow
in top panels). Color variations from lighter to darker shades of blue represent levels of gene expression from lower to
higher, respectively. Gene names are listed below the panels, and asterisks denote genes that have been previously
recognized as regulated by IFN. Siglec-1 (shown as sialoadhesin) is represented by 2 probe sets.”
DOI 10.1002/art.22730
In the article by Westhovens et al published in the April 2006 issue of Arthritis & Rheumatism (pp. 1075–1086), there were
several errors under the Dose Escalation heading in the Results section. The two paragraphs under that heading should
have read as follows (corrections in italics):
Of the 329 patients who entered the dose-escalation phase of the study, 100 patients (30.4%) received a dose escalation
because they did not meet the criteria for response at week 22 or because they initially met the response criteria at week
22 but later met the criteria for a disease flare. Fifty-nine patients (17.9%) received 1 dose increase for a total of 4.5 mg/kg,
21 patients (6.4%) received 2 increases for a total dose of 6.0 mg/kg, 13 patients (4.0%) received 3 increases for a total
of 7.5 mg/kg, 7 patients (2.1%) received 4 increases for a total dose of 9 mg/kg, the latter being the maximum allowed by
the study protocol. Nine additional patients received dose escalation in error; i.e., they did not meet the criteria for lack of
response or flare.
Improved efficacy was observed in the patients in group 2 who received dose escalations (13). Nevertheless, patients
in group 2 who continued to receive 3 mg/kg infliximab in combination with MTX had similar frequencies of infections,
serious infections, or other adverse events compared with those who received dose escalations. Of the 109 patients in
group 2 who received a dose escalation, 77 (71%) reported experiencing an adverse event, 14 (13%) reported experiencing
a serious adverse event, 39 (36%) reported developing an infection, and 2 (2%) reported developing a serious infection
between weeks 22 and 54. Of the 220 patients in group 2 who did not receive a dose escalation at any time, 160 (73%)
reported experiencing an adverse event, 19 (9%) reported experiencing a serious adverse event, 80 (36%) reported
developing an infection, and 5 (2%) reported developing a serious infection between baseline and week 54. The mean
duration of treatment was 30.6 weeks for patients with a dose escalation and 31.0 weeks for patients without a dose
escalation.
The changes do not affect the overall conclusions of the study.
We regret the errors.
1675